Trial Profile
A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimepinostat (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Dec 2018 Status changed to discontinued.
- 20 Jan 2017 Planned primary completion date changed from 1 Sep 2024 to 30 Sep 2024.
- 30 Dec 2016 Status changed from not yet recruiting to recruiting.